Clinical Trials
25 trialsTretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer
Weill Medical College of Cornell University
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
Dartmouth-Hitchcock Medical Center
Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
Alliance for Clinical Trials in Oncology
Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer
The Methodist Hospital Research Institute
Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney Cancer
National Cancer Institute (NCI)
Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
University of New Mexico
Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically
National Cancer Institute (NCI)
Fluorouracil and Biological Therapy in Treating Patients With Metastatic Kidney or Colorectal Cancer
National Cancer Institute (NCI)
Interferon Alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer
National Cancer Institute (NCI)
Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Memorial Sloan Kettering Cancer Center
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
National Cancer Institute (NCI)
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma
National Cancer Institute (NCI)
ARCC
Pfizer
Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer
Centre Leon Berard
Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients Who Have Undergone Surgery for Kidney Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer
European Organisation for Research and Treatment of Cancer - EORTC
SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
City of Hope Medical Center
High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma
Hoag Memorial Hospital Presbyterian
Biological Therapy in Treating Patients With Metastatic Cancer
Hoag Memorial Hospital Presbyterian
Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer
Kidney Cancer Research Bureau
Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens
Kidney Cancer Research Bureau
Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer
National Cancer Institute (NCI)